# A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars

> **NCT00825916** · PHASE2 · COMPLETED · sponsor: **Capstone Therapeutics** · enrollment: 59 (actual)

## Conditions studied

- Scar Prevention
- Scar Reduction

## Interventions

- **DRUG:** AZX100 Drug Product
- **DRUG:** AZX100 Drug Product
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00825916
- **Lead sponsor:** Capstone Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2012-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00825916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00825916, "A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00825916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*